SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Bentley R. Mycophenolic acid: a one hundred year odyssey from antibiotic to immunosuppressant [Review][201 refs]. Chem Rev 2000; 100: 380125.
  • 2
    Alsberg CL, Black F. Contribution to the study of maize deterioration; biochemical and toxicological investigations of Penicillium puberulum and Penicillium stoloniferum. U S Dept Agr, Bureau Plant Ind, Bull 1913; 270: 147.
  • 3
    Carter SB, Franklin TJ, Jones DF, Leonard BJ, Mills SD, Turner RW, Turner WB. Mycophenolic acid: an anti-cancer compound with unusual properties. Nature 1969; 223: 84850.
  • 4
    Allison AC. Mechanisms of action of mycophenolate mofetil. Lupus 2005; 14 (Suppl. 1): s28.
  • 5
    Mele TS, Halloran PF. The use of mycophenolate mofetil in transplant recipients. [Review][130 refs]. Immunopharmacology 2000; 47: 21545.
  • 6
    Chong CR, Qian DZ, Pan F, Wei Y, Pili R, Sullivan DJ, Jr, Liu JO. Identification of type 1 inosine monophosphate dehydrogenase as an antiangiogenic drug target. J Med Chem 2006; 49: 267780.
  • 7
    Mehling A, Grabbe S, Voskort M, Schwarz T, Luger TA, Beissert S. Mycophenolate mofetil impairs the maturation and function of murine dendritic cells. J Immunol 2000; 165: 237481.
  • 8
    Haug C, Schmid-Kotsas A, Linder T, Jehle PM, Bachem MG, Gruenert A, Rozdzinski E. The immunosuppressive drug mycophenolic acid reduces endothelin-1 synthesis in endothelial cells and renal epithelial cells. Clin Sci 2002; 103: 76S80S.
  • 9
    Roche. Summary of Product Characteristics Data Sheet Cellcept 500 mg Tablets. Welwyn Garden City, Hertfordshire: Datapharm Communications Ltd, 2009. Available at: http://www.medicines.org.uk/emc/document.aspx?documentId=1680&doctype=SPC (last accessed October 2011).
  • 10
    Roche. Cellcept US label. 2009. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/050722s024,050723s023,050758s022,050759s028lbl.pdf (last accessed October 2011).
  • 11
    Shipkova M, Armstrong VW, Wieland E, Niedmann PD, Schutz E, Brenner-Weiss G, Voihsel M, Braun F, Oellerich M. Identification of glucoside and carboxyl-linked glucuronide conjugates of mycophenolic acid in plasma of transplant recipients treated with mycophenolate mofetil. Br J Pharmacol 1999; 126: 107582.
  • 12
    Shipkova M, Armstrong VW, Weber L, Niedmann PD, Wieland E, Haley J, Tonshoff B, Oellerich M, German Study Group on Mycophenolate Mofetil Therapy in Pediatric Renal Transplant R. Pharmacokinetics and protein adduct formation of the pharmacologically active acyl glucuronide metabolite of mycophenolic acid in pediatric renal transplant recipients. Ther Drug Monit 2002; 24: 3909.
  • 13
    Shipkova M, Schutz E, Besenthal I, Fraunberger P, Wieland E, Shipkova M, Schutz E, Besenthal I, Fraunberger P, Wieland E. Investigation of the crossreactivity of mycophenolic acid glucuronide metabolites and of mycophenolate mofetil in the Cedia MPA assay. Ther Drug Monit 2010; 32: 7985.
  • 14
    Pranzatelli MR, Tate ED, Travelstead AL, Baumgardner CA, Gowda NV, Halthore SN, Kerstan P, Kossak BD, Mitchell WG, Taub JW. Insights on chronic-relapsing opsoclonus-myoclonus from a pilot study of mycophenolate mofetil. J Child Neurol 2009; 24: 31622.
  • 15
    Dorresteijn EM, Kist-van Holthe JE, Levtchenko EN, Nauta J, Hop WC, van der Heijden AJ. Mycophenolate mofetil versus cyclosporine for remission maintenance in nephrotic syndrome. Pediatr Nephrol 2008; 23: 201320.
  • 16
    De S, Al-Nabhani D, Thorner P, Cattran D, Piscione TD, Licht C. Remission of resistant MPGN type I with mycophenolate mofetil and steroids. Pediatr Nephrol 2009; 24: 597600.
  • 17
    Aw MM, Brown NW, Itsuka T, Gonde CE, Adams JE, Heaton ND, Tredger JM, Mieli-Vergani G, Dhawan A. Mycophenolic acid pharmacokinetics in pediatric liver transplant recipients. Liver Transpl 2003; 9: 3838.
  • 18
    David-Neto E, Pereira Araujo LM, Sumita NM, Mendes ME, Ribeiro Castro MC, Alves CF, Kakehashi E, Romano P, Yagyu EM, Queiroga M, Nahas WC, Ianhez LE. Mycophenolic acid pharmacokinetics in stable pediatric renal transplantation. Pediatr Nephrol 2003; 18: 26672.
  • 19
    Bhatia M, Militano O, Jin Z, Figurski M, Shaw L, Moore V, Morris E, Tallamy B, van deVen C, Ayello J, Baxter-Lowe L, Satwani P, George D, Bradley MB, Garvin J, Cairo MS. An age-dependent pharmacokinetic study of intravenous and oral mycophenolate mofetil in combination with tacrolimus for GVHD prophylaxis in pediatric allogeneic stem cell transplantation recipients. Biol Blood Marrow Transplant 2010; 16: 33343.
  • 20
    Sagcal-Gironella ACP, Fukuda T, Wiers K, Cox S, Nelson S, Dina B, Sherwin CMT, Klein-Gitelman MS, Vinks AA, Brunner HI. Pharmacokinetics and pharmacodynamics of mycophenolic acid and their relation to response to therapy of childhood-onset systemic lupus erythematosus. Semin Arthritis Rheum 2011; 40: 30713.
  • 21
    Tredger JM, Brown NW, Adams J, Gonde CE, Dhawan A, Rela M, Heaton N. Monitoring mycophenolate in liver transplant recipients: toward a therapeutic range. Liver Transpl 2004; 10: 492502.
  • 22
    Aigrain EJ, Shaghaghi EK, Baudouin V, Popon M, Loirat C. Pharmacokinetics of mycophenolate mofetil in eight pediatric renal transplant patients. Transplant Proc 2000; 32: 38890.
  • 23
    Zhao W, Elie V, Baudouin V, Bensman A, Andre JL, Brochard K, Broux F, Cailliez M, Loirat C, Jacqz-Aigrain E. Population pharmacokinetics and Bayesian estimator of mycophenolic acid in children with idiopathic nephrotic syndrome. Br J Clin Pharmacol 2010; 69: 35866.
  • 24
    Zhao W, Fakhoury M, Deschenes G, Roussey G, Brochard K, Niaudet P, Tsimaratos M, Andre JL, Cloarec S, Cochat P, Bensman A, Azougagh S, Jacqz-Aigrain E. Population pharmacokinetics and pharmacogenetics of mycophenolic acid following administration of mycophenolate mofetil in de novo pediatric renal-transplant patients. J Clin Pharmacol 2010; 50: 128091.
  • 25
    Antoniadis A, Papachristou F, Gakis D, Takoudas D, Sotiriou I. Comparison between mycophenolate mofetil and azathioprine based immunosuppression in pediatric renal transplantation from living related donors. Transplant Proc 1998; 30: 40856.
  • 26
    Grenda R. Effects of steroid avoidance and novel protocols on growth in paediatric renal transplant patients. Pediatr Nephrol 2010; 25: 74752.
  • 27
    Olney RC. Mechanisms of impaired growth: effect of steroids on bone and cartilage. Horm Res 2009; 72 (Suppl. 1): 305.
  • 28
    Birkeland SA, Larsen KE, Rohr N. Pediatric renal transplantation without steroids. Pediatr Nephrol 1998; 12: 8792.
  • 29
    Silverstein DM, Aviles DH, LeBlanc PM, Jung FF, Vehaskari VM. Results of one-year follow-up of steroid-free immunosuppression in pediatric renal transplant patients. Pediatr Transplant 2005; 9: 58997.
  • 30
    Nematalla AH, Bakr MA, Gheith OA, Elagroudy AE, Elshahawy M, Aghoneim M. Steroid-avoidance immunosuppression regimen in live-donor renal allotransplant recipients: a prospective, randomized, controlled study. Exp Clin Transplant 2007; 5: 6739.
  • 31
    Hocker B, Weber LT, Feneberg R, Drube J, John U, Fehrenbach H, Pohl M, Zimmering M, Frund S, Klaus G, Wuhl E, Tonshoff B. Prospective, randomized trial on late steroid withdrawal in pediatric renal transplant recipients under cyclosporine microemulsion and mycophenolate mofetil. Transplantation 2009; 87: 93441.
  • 32
    Hocker B, Weber LT, Feneberg R, Drube J, John U, Fehrenbach H, Pohl M, Zimmering M, Frund S, Klaus G, Wuhl E, Tonshoff B. Improved growth and cardiovascular risk after late steroid withdrawal: 2-year results of a prospective, randomised trial in paediatric renal transplantation. Nephrol Dial Transplant 2010; 25: 61724.
  • 33
    Chavers BM, Chang YC, Gillingham KJ, Matas A. Pediatric kidney transplantation using a novel protocol of rapid (6-day) discontinuation of prednisone: 2-year results. Transplantation 2009; 88: 23741.
  • 34
    Grenda R, Watson A, Trompeter R, Tonshoff B, Jaray J, Fitzpatrick M, Murer L, Vondrak K, Maxwell H, van Damme-Lombaerts R, Loirat C, Mor E, Cochat P, Milford DV, Brown M, Webb NJA. A randomized trial to assess the impact of early steroid withdrawal on growth in pediatric renal transplantation: the TWIST study. Am J Transplant 2010; 10: 82836.
  • 35
    Krischock L, Gullett A, Bockenhauer D, Rees L, Trompeter RS, Marks SD. Calcineurin-inhibitor free immunosuppression with mycophenolate mofetil and corticosteroids in paediatric renal transplantation improves renal allograft function without increasing acute rejection. Pediatr Transplant 2009; 13: 47581.
  • 36
    Cransberg K, Cornelissen M, Lilien M, Van Hoeck K, Davin JC, Nauta J. Maintenance immunosuppression with mycophenolate mofetil and corticosteroids in pediatric kidney transplantation: temporary benefit but not without risk. Transplantation 2007; 83: 10417.
  • 37
    Alousi AM, Weisdorf DJ, Logan BR, Bolanos-Meade J, Carter S, Difronzo N, Pasquini M, Goldstein SC, Ho VT, Hayes-Lattin B, Wingard JR, Horowitz MM, Levine JE, Blood, Marrow Transplant Clinical Trials N. Etanercept, mycophenolate, denileukin, or pentostatin plus corticosteroids for acute graft-versus-host disease: a randomized phase 2 trial from the Blood and Marrow Transplant Clinical Trials Network. Blood 2009; 114: 5117.
  • 38
    Sinclair A, Appel G, Dooley MA, Ginzler E, Isenberg D, Jayne D, Wofsy D, Solomons N. Mycophenolate mofetil as induction and maintenance therapy for lupus nephritis: rationale and protocol for the randomized, controlled Aspreva Lupus Management Study (ALMS). Lupus 2007; 16: 97280.
  • 39
    Hocker B, van Gelder T, Martin-Govantes J, Machado P, Tedesco H, Rubik J, Dehennault M, Garcia Meseguer C, Tonshoff B, Group FS. Comparison of MMF efficacy and safety in paediatric vs. adult renal transplantation: subgroup analysis of the randomised, multicentre FDCC trial. Nephrol Dial Transplant 2011; 26: 10739.
  • 40
    Benfield MR, Symons JM, Bynon S, Eckhoff D, Herrin J, Harmon W, Kohaut E. Mycophenolate mofetil in pediatric renal transplantation. Pediatr Transplant 1999; 3: 337.
  • 41
    GlaxoSmithKline. Imuran Summary of Product Characteristics. 2009.
  • 42
    Al-Akash S, Al-Makdama A. Mycophenolate mofetil in children with steroid-dependent and/or frequently relapsing nephrotic syndrome. Ann Saudi Med 2005; 25: 3804.
  • 43
    de Mello VR, Rodrigues MT, Mastrocinque TH, Martins SPL, de Andrade OVB, Guidoni EBM, Scheffer DK, Martini Filho D, Toporovski J, Benini V. Mycophenolate mofetil in children with steroid/cyclophosphamide-resistant nephrotic syndrome. Pediatr Nephrol 2010; 25: 45360.
  • 44
    Chardot C, Nicoluzzi JE, Janssen M, Sokal E, Lerut J, Otte JB, Reding R. Use of mycophenolate mofetil as rescue therapy after pediatric liver transplantation. Transplantation 2001; 71: 2249.
  • 45
    Dipchand AI, Benson L, McCrindle BW, Coles J, West L. Mycophenolate mofetil in pediatric heart transplant recipients: a single-center experience. Pediatr Transplant 2001; 5: 1128.
  • 46
    BNF for Children 2011–2012. London: BMJ Group, Pharmaceutical Press and RCPCH Publications Ltd, 2011.
  • 47
    Filler G. Value of therapeutic drug monitoring of MMF therapy in pediatric transplantation. [Review][46 refs]. Pediatr Transplant 2006; 10: 70711.
  • 48
    Pape L, Ehrich JH, Offner G. Long-term follow-up of pediatric transplant recipients: mycophenolic acid trough levels are not a good indicator for long-term graft function. Clin Transplant 2004; 18: 5769.
  • 49
    Filler G, Foster J, Berard R, Mai I, Lepage N. Age-dependency of mycophenolate mofetil dosing in combination with tacrolimus after pediatric renal transplantation. Transplant Proc 2004; 36: 132731.
  • 50
    Rousseau A, Laroche M-L, Venisse N, Loichot-Roselmac C, Turcant A, Hoizey G, Compagnon P, Hary L, Debruyne D, Saivin S, Jacqz-Aigrain E, Buchler M, Villeneuve C, Vergnenegre A, Le Meur Y, Marquet P. Cost-effectiveness analysis of individualized mycophenolate mofetil dosing in kidney transplant patients in the APOMYGRE trial. Transplantation 2010; 89: 125562.
  • 51
    Tonshoff B, David-Neto E, Ettenger R, Filler G, van Gelder T, Goebel J, Kuypers DRJ, Tsai E, Vinks AA, Weber LT, Zimmerhackl LB. Pediatric aspects of therapeutic drug monitoring of mycophenolic acid in renal transplantation. Transplant Rev 2011; 25: 7889.
  • 52
    Fukuda T, Goebel J, Thogersen H, Maseck D, Cox S, Logan B, Sherbotie J, Seikaly M, Vinks AA. Inosine monophosphate dehydrogenase (IMPDH) activity as a pharmacodynamic biomarker of mycophenolic acid effects in pediatric kidney transplant recipients. J Clin Pharmacol 2011; 51: 30920.
  • 53
    Levesque E, Benoit-Biancamano MO, Delage R, Couture F, Guillemette C. Pharmacokinetics of mycophenolate mofetil and its glucuronide metabolites in healthy volunteers. Pharmacogenomics 2008; 9: 86979.
  • 54
    Hedstrom L. IMP dehydrogenase: structure, mechanism, and inhibition. [Review][275 refs]. Chem Rev 2009; 109: 290328.
  • 55
    Winnicki W, Weigel G, Sunder-Plassmann G, Bajari T, Winter B, Herkner H, Sengoelge G. An inosine 5'-monophosphate dehydrogenase 2 single-nucleotide polymorphism impairs the effect of mycophenolic acid. In, edJournal TP: Nature Publishing Group, 2009.
  • 56
    Ohmann EL, Burckart GJ, Brooks MM, Chen Y, Pravica V, Girnita DM, Zeevi A, Webber SA, Ohmann EL, Burckart GJ, Brooks MM, Chen Y, Pravica V, Girnita DM, Zeevi A, Webber SA. Genetic polymorphisms influence mycophenolate mofetil-related adverse events in pediatric heart transplant patients. J Heart Lung Transplant 2010; 29: 50916.
  • 57
    Ohmann EL, Burckart GJ, Chen Y, Pravica V, Brooks MM, Zeevi A, Webber SA. Inosine 5′-monophosphate dehydrogenase 1 haplotypes and association with mycophenolate mofetil gastrointestinal intolerance in pediatric heart transplant patients. Pediatr Transplant 2010; 14: 8915.
  • 58
    Prausa SE, Fukuda T, Maseck D, Curtsinger KL, Liu C, Zhang K, Nick TG, Sherbotie JR, Ellis EN, Goebel J, Vinks AA. UGT genotype may contribute to adverse events following medication with mycophenolate mofetil in pediatric kidney transplant recipients. Clin Pharmacol Ther 2009; 85: 495500.
  • 59
    NIHR. Medicines for children research network. 2010. Available at: http://www.adric.org.uk/ (last accessed January 2012).
  • 60
    Gorelik L, Reid C, Testa M, Brickelmaier M, Bossolasco S, Pazzi A, Bestetti A, Carmillo P, Wilson E, McAuliffe M, Tonkin C, Carulli JP, Lugovskoy A, Lazzarin A, Sunyaev S, Simon K, Cinque P. Progressive multifocal leukoencephalopathy (PML) development is associated with mutations in JC virus capsid protein VP1 that change its receptor specificity. J Infect Dis 2011; 204: 10314.
  • 61
    Weber SC, Uhlenberg B, Raile K, Querfeld U, Muller D. Polyoma virus-associated progressive multifocal leukoencephalopathy after renal transplantation: regression following withdrawal of mycophenolate mofetil. Pediatr Transplant 2011; 15: E1924.
  • 62
    Pape L, Ahlenstiel T, Kreuzer M, Ehrich JH. Improved gastrointestinal symptom burden after conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in kidney transplanted children. Pediatr Transplant 2008; 12: 6402.
  • 63
    Pape L, Ahlenstiel T. Is EC-MPS effective in reducing GI toxicity of MPA? At what price? Pediatr Transplant 2009; 13: 65960.
  • 64
    Reyes H, Hernandez AM, Valverde S, Cataneo A, Mendoza A, Barrera I, Ortiz L, Garcia-Roca P, Lopez-Martinez B, Castaneda-Hernandez G, Medeiros M. Efficacy and safety of conversion of mycophenolate mofetil to enteric-coated mycophenolate sodium in Mexican renal transplant children. Pediatr Transplant 2010; 14: 74652.
  • 65
    Daliphard S, Accard F, Delattre C, Toupance O, Guyot C, Mechinaud F, Chassaing A, Hourmant M, Rousset P, Potron G. Reversible abnormal chromatin clumping in granulocytes from six transplant patients treated with mycophenolate mofetil: a rare adverse effect mimicking abnormal chromatin clumping syndrome. Br J Haematol 2002; 116: 7267.
  • 66
    Patiroglu T, Ozcan A, Karakukcu M, Ozdemir MA, Poyrazoglu G, Canpolat M, Unal E. Mycophenolate mofetil-induced pseudotumor cerebri in a boy with autoimmune lymphoproliferative disease. Childs Nerv Syst 2011; 27: 8535.
  • 67
    Phatak UP, Seo-Mayer P, Jain D, Selbst M, Husain S, Pashankar DS. Mycophenolate mofetil-induced colitis in children. J Clin Gastroenterol 2009; 43: 9679.
  • 68
    Reynolds BC, Paton JY, Howatson AG, Ramage IJ. Reversible chronic pulmonary fibrosis associated with MMF in a pediatric patient: a case report. Pediatr Transplant 2008; 12: 22831.
  • 69
    Pijnenburg MW, Cransberg K, Wolff E, Bouquet J, Merkus PJ. Bronchiectasis in children after renal or liver transplantation: a report of five cases. Pediatr Transplant 2004; 8: 714.
  • 70
    Merkus PJ, Pijnenburg M, Cransberg K. Mycophenolate mofetil and bronchiectasis in pediatric transplant patients. Transplantation 2006; 82: 1386.
  • 71
    Koshy AN, Strong D, Earles G, Fassett RG. Congenital malformations with low-dose mycophenolate mofetil after kidney transplantation. Nephrology 2010; 15: 1335.
  • 72
    Lin AE, Singh KE, Strauss A, Nguyen S, Rawson K, Kimonis VE. An additional patient with mycophenolate mofetil embryopathy: cardiac and facial analyses. Am J Med Genet 2011; Part A. 155A: 74856.
  • 73
    Schreiner MS. Paediatric clinical trials: redressing the imbalance. [Review][86 refs]. Nat Rev Drug Discov 2003; 2: 94961.
  • 74
    Sammons HM, Choonara I. What is happening to improve drug therapy in children? Paediatr Child Health 2007; 17: 10810.
  • 75
    Pandolfini C, Bonati M, Rossi V, Santoro E, Choonara I, Naylor C, Sammons H, Jacqz-Aigrain E, Zarrabian S, Arnau JM, Castel JM, Danes I, Fuentes I. The DEC-net European register of paediatric drug therapy trials: contents and context. Eur J Clin Pharmacol 2008; 64: 6117.
  • 76
    Sammons HM, Gray C, Hudson H, Cherrill J, Choonara I. Safety in paediatric clinical trials – a 7-year review. Acta Paediatr 2008; 97: 4747.
  • 77
    Shaddy RE, Fuller TC, Anderson JB, Lambert LM, Brinkman MK, Profaizer T, Hawkins JA. Mycophenolic mofetil reduces the HLA antibody response of children to valved allograft implantation. Ann Thorac Surg 2004; 77: 17349.
  • 78
    Ostronoff F, Ostronoff M, Souto-Maior AP, Domingues M, Sucupira A, Manso DA, de Lima AK, Monteiro PG, Florencio R, Calixto R. Prospective trial of mycophenolate mofetil-cyclosporine A prophylaxis for acute GVHD after G-CSF stimulated allogeneic bone marrow transplantation with HLA-identical sibling donors in patients with severe aplastic anemia and hematological malignancies. Clin Transplant 2009; 23: 338.
  • 79
    Tannuri U, Gibelli NE, Maksoud-Filho JG, Santos MM, Pinho-Apezzato ML, Velhote MC, Ayoub AA, Silva MM, Maksoud JG. Mycophenolate mofetil promotes prolonged improvement of renal dysfunction after pediatric liver transplantation: experience of a single center. Pediatr Transplant 2007; 11: 826.
  • 80
    Tzakis AG, Weppler D, Khan MF, Koutouby R, Romero R, Viciana AL, Raskin J, Nery JR, Thompson J. Mycophenolate mofetil as primary and rescue therapy in intestinal transplantation. Transplant Proc 1998; 30: 26779.
  • 81
    Buratti S, Szer IS, Spencer CH, Bartosh S, Reiff A. Mycophenolate mofetil treatment of severe renal disease in pediatric onset systemic lupus erythematosus. J Rheumatol 2001; 28: 21038.
  • 82
    Falcini F, Capannini S, Martini G, La Torre F, Vitale A, Mangiantini F, Nacci F, Cerinic MM, Cimaz R, Zulian F. Mycophenolate mofetil for the treatment of juvenile onset SLE: a multicenter study. Lupus 2009; 18: 13943.
  • 83
    Rivera TL, Belmont HM, Malani S, Latorre M, Benton L, Weisstuch J, Barisoni L, Tseng CE, Izmirly PM, Buyon JP, Askanase AD. Current therapies for lupus nephritis in an ethnically heterogeneous cohort. J Rheumatol 2009; 36: 298305.
  • 84
    Wong SN, Chan WK, Hui J, Chim S, Lee TL, Lee KP, Leung LC, Tse NK, Yuen SF. Membranous lupus nephritis in Chinese children – a case series and review of the literature. [Review][24 refs]. Pediatr Nephrol 2009; 24: 198996.
  • 85
    Posalski JD, Ishimori M, Wallace DJ, Weisman MH. Does mycophenolate mofetil prevent extra-renal flares in systemic lupus erythematosus? Results from an observational study of patients in a single practice treated for up to 5 years. Lupus 2009; 18: 51621.
  • 86
    Aragon E, Chan YH, Ng KH, Lau YW, Tan PH, Yap HK. Good outcomes with mycophenolate-cyclosporine-based induction protocol in children with severe proliferative lupus nephritis. Lupus 2010; 19: 96573.
  • 87
    Kazyra I, Pilkington C, Marks SD, Tullus K. Mycophenolate mofetil treatment in children and adolescents with lupus. Arch Dis Child 2010; 95: 105961.
  • 88
    Martini G, Ramanan AV, Falcini F, Girschick H, Goldsmith DP, Zulian F. Successful treatment of severe or methotrexate-resistant juvenile localized scleroderma with mycophenolate mofetil. Rheumatology 2009; 48: 14103.
  • 89
    Meriggioli MN, Ciafaloni E, Al-Hayk KA, Rowin J, Tucker-Lipscomb B, Massey JM, Sanders DB. Mycophenolate mofetil for myasthenia gravis: an analysis of efficacy, safety, and tolerability. Neurology 2003; 61: 143840.
  • 90
    Aw MM, Dhawan A, Samyn M, Bargiota A, Mieli-Vergani G. Mycophenolate mofetil as rescue treatment for autoimmune liver disease in children: a 5-year follow-up. J Hepatol 2009; 51: 15660.
  • 91
    Rao VK, Dugan F, Dale JK, Davis J, Tretler J, Hurley JK, Fleisher T, Puck J, Straus SE. Use of mycophenolate mofetil for chronic, refractory immune cytopenias in children with autoimmune lymphoproliferative syndrome. Br J Haematol 2005; 129: 5348.
  • 92
    Thorne JE, Jabs DA, Qazi FA, Nguyen QD, Kempen JH, Dunn JP. Mycophenolate mofetil therapy for inflammatory eye disease. Ophthalmology 2005; 112: 14727.
  • 93
    Doycheva D, Deuter C, Stuebiger N, Biester S, Zierhut M. Mycophenolate mofetil in the treatment of uveitis in children. Br J Ophthalmol 2007; 91: 1804.
  • 94
    Sobrin L, Christen W, Foster CS. Mycophenolate mofetil after methotrexate failure or intolerance in the treatment of scleritis and uveitis. Ophthalmology 2008; 115: 141621.
  • 95
    Chang PY, Giuliari GP, Shaikh M, Thakuria P, Makhoul D, Foster CS. Mycophenolate mofetil monotherapy in the management of paediatric uveitis. Eye 2011; 25: 42735.
  • 96
    Trachtman H, Christen E, Frank R, Rini J, Palestro C, Perelstein E, Weiss L, Tarapore F, Fortune S, Horowitz J. Pilot study of mycophenolate mofetil for treatment of kidney disease due to congenital urinary tract disorders in children. Am J Kidney Dis 2008; 52: 70615.
  • 97
    Rouster-Stevens KA, Morgan GA, Wang D, Pachman LM. Mycophenolate mofetil: a possible therapeutic agent for children with juvenile dermatomyositis. Arthritis Care Res 2010; 62: 144651.
  • 98
    Barletta GM, Smoyer WE, Bunchman TE, Flynn JT, Kershaw DB. Use of mycophenolate mofetil in steroid-dependent and -resistant nephrotic syndrome. Pediatr Nephrol 2003; 18: 8337.
  • 99
    Hogg RJ, Fitzgibbons L, Bruick J, Bunke M, Ault B, Baqi N, Trachtman H, Swinford R. Mycophenolate mofetil in children with frequently relapsing nephrotic syndrome: a report from the Southwest Pediatric Nephrology Study Group. Clin J Am Soc Nephrol CJASN 2006; 1: 11738.
  • 100
    Afzal K, Bagga A, Menon S, Hari P, Jordan SC. Treatment with mycophenolate mofetil and prednisolone for steroid-dependent nephrotic syndrome. Pediatr Nephrol 2007; 22: 205965.
  • 101
    Okada M, Sugimoto K, Yagi K, Yanagida H, Tabata N, Takemura T. Mycophenolate mofetil therapy for children with intractable nephrotic syndrome. Pediatr Int 2007; 49: 9337.
  • 102
    Wong CS, Fink CA, Baechle J, Harris AA, Staples AO, Brandt JR. C1q nephropathy and minimal change nephrotic syndrome. Pediatr Nephrol 2009; 24: 7617.
  • 103
    Li Z, Duan C, He J, Wu T, Xun M, Zhang Y, Yin Y. Mycophenolate mofetil therapy for children with steroid-resistant nephrotic syndrome. Pediatr Nephrol 2010; 25: 8838.
  • 104
    Gargah TTG, Lakhoua MR. Mycophenolate mofetil in treatment of childhood steroid-resistant nephrotic syndrome. J Nephrol 2011; 24: 2037.
  • 105
    Heller M, Shin HT, Orlow SJ, Schaffer JV. Mycophenolate mofetil for severe childhood atopic dermatitis: experience in 14 patients. Br J Dermatol 2007; 157: 12732.
  • 106
    Scheinberg P, Nunez O, Wu C, Young NS. Treatment of severe aplastic anaemia with combined immunosuppression: anti-thymocyte globulin, ciclosporin and mycophenolate mofetil. Br J Haematol 2006; 133: 60611.
  • 107
    Gottlieb PA, Quinlan S, Krause-Steinrauf H, Greenbaum CJ, Wilson DM, Rodriguez H, Schatz DA, Moran AM, Lachin JM, Skyler JS, Type 1 Diabetes TrialNet MMFDZBSG. Failure to preserve beta-cell function with mycophenolate mofetil and daclizumab combined therapy in patients with new- onset type 1 diabetes. Diabetes Care 2010; 33: 82632.